SHP.L : Summary for SHIRE PLC ORD 5P - Yahoo Finance

U.S. Markets closed

Shire plc (SHP.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,619.00-42.50 (-0.91%)
At close: 5:01PM GMT
People also watch
SN.LWPP.LSMIN.LSDR.LREL.L
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4,661.50
Open4,650.00
Bid4,600.00 x 51000
Ask4,710.00 x 53800
Day's Range4,606.00 - 4,702.00
52 Week Range2,707.19 - 5,377.00
Volume1,123,171
Avg. Volume2,336,706
Market Cap41.44B
Beta1.65
PE Ratio (TTM)211.88
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.26 (0.46%)
Ex-Dividend DateN/A
1y Target EstN/A
  • MarketWatch3 days ago

    FTSE 100 continues record run, rising for 14th day in a row

    U.K. stocks gained for a 14th straight day on Friday, extending their record winning run as a soft pound helped spur investors to buy into British multinationals.

  • Shire Plc breached its 50 day moving average in a Bearish Manner : SHP-GB : January 13, 2017
    Capital Cube4 days ago

    Shire Plc breached its 50 day moving average in a Bearish Manner : SHP-GB : January 13, 2017

    Categories: Europe Stock Alerts Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Shire Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • American City Business Journals4 days ago

    Lawsuit accuses Shire of monopolizing market for ADHD drug

    A new class action lawsuit accuses Shire plc’s U.S. subsidiary in Lexington of monopolizing the market for its ADHD drug Intuniv by conspiring with Actavis to delay the commercial release of a cheaper generic version. New Jersey-based Actavis (NYSE:ACT) won FDA approval to launch a cheaper, generic version of Intuniv in October 2012. Shire was effectively paying Actavis “tens of millions of dollars” to maintain a monopoly, the suit claimed.